Question

Gama-Smith, a pharmaceutical company, develops new drugs for COVID-19 with other pharmaceutical companies that have the...

Gama-Smith, a pharmaceutical company, develops new drugs for COVID-19 with other pharmaceutical companies that have the appropriate production facilities.

When Gama-Smith acquires a stake in a development project, it makes an initial payment to the other pharmaceutical company. It then makes a series of further stage payments until the drug development is complete and it has been approved by the relevant authorities. In the financial statements for the year ended 30 June 2019, Gama-Smith has treated the different stakes in the development projects as separate intangible assets because of the anticipated future economic benefits related to Gama-Smith’s ownership of the drug rights. However, in the year to 30 June 2020, the directors of Gama-Smith decided that all such intangible assets were to be expensed as research and development costs as they were unsure as to whether the payments should have been initially recognised as intangible assets. This write off was to be treated as a change in an accounting estimate.

Required:

Discuss the implications for Gama-Smith’s financial statements for both the years ended 30 June 2019 and 2020 if the recognition criteria in AASB 138 for an intangible asset were met as regards the stakes in the development projects above. Your answer should also briefly consider the implications if the recognition criteria were not met.                                                                                                

Homework Answers

Answer #1

the stakes aquired by gama smith for development projects, can be treated as current or non current investments in accordance with their future economic benefits.

current investments are investments which gives benefit for upto one year and ready for sale within one year, non current investments are the vice versa of current investments

these both envestments are recognised as assets in financial statements as current asset or non current assets,

As stakes hold by gama smith on 30 june 2020 is non current investment as not ready for sale upto one year. thats why the recognition critera of directer is wrong. these stakes were to be recognised in assets side of financial statement under non current investment headig.

Know the answer?
Your Answer:

Post as a guest

Your Name:

What's your source?

Earn Coins

Coins can be redeemed for fabulous gifts.

Not the answer you're looking for?
Ask your own homework help question
Similar Questions
Amy Dyken, controller at Shamrock Pharmaceutical Industries, a public company, is currently preparing the calculation for...
Amy Dyken, controller at Shamrock Pharmaceutical Industries, a public company, is currently preparing the calculation for basic and diluted earnings per share and the related disclosure for Shamrock’s financial statements. Below is selected financial information for the fiscal year ended June 30, 2020. Shamrock Pharmaceutical Industries Selected Balance Sheet Information June 30, 2020 Long-term debt    Notes payable, 10% $1,020,000    9% convertible bonds payable 5,030,000    10% bonds payable 5,950,000      Total long-term debt $12,000,000 Shareholders’ equity    Preferred stock, 5% cumulative, $50 par...
Amy Dyken, controller at Fitzgerald Pharmaceutical Industries, a public company, is currently preparing the calculation for...
Amy Dyken, controller at Fitzgerald Pharmaceutical Industries, a public company, is currently preparing the calculation for basic and diluted earnings per share and the related disclosure for Fitzgerald’s financial statements. Below is selected financial information for the fiscal year ended June 30, 2020. Fitzgerald Pharmaceutical Industries Selected Balance Sheet Information June 30, 2020 Long-term debt    Notes payable, 10% $1,000,000    8% convertible bonds payable 5,000,000    10% bonds payable 6,000,000      Total long-term debt $12,000,000 Shareholders’ equity    Preferred stock, 6% cumulative, $50 par...
Amy Dyken, controller at Sandhill Pharmaceutical Industries, a public company, is currently preparing the calculation for...
Amy Dyken, controller at Sandhill Pharmaceutical Industries, a public company, is currently preparing the calculation for basic and diluted earnings per share and the related disclosure for Sandhill’s financial statements. Below is selected financial information for the fiscal year ended June 30, 2020. Sandhill Pharmaceutical Industries Selected Balance Sheet Information June 30, 2020 Long-term debt    Notes payable, 11% $990,000    7% convertible bonds payable 5,080,000    11% bonds payable 6,120,000      Total long-term debt $12,190,000 Shareholders’ equity    Preferred stock, 6% cumulative, $50 par...
Amy Dyken, controller at Ayayai Pharmaceutical Industries, a public company, is currently preparing the calculation for...
Amy Dyken, controller at Ayayai Pharmaceutical Industries, a public company, is currently preparing the calculation for basic and diluted earnings per share and the related disclosure for Ayayai’s financial statements. Below is selected financial information for the fiscal year ended June 30, 2020. Ayayai Pharmaceutical Industries Selected Balance Sheet Information June 30, 2020 Long-term debt    Notes payable, 10% $1,000,000    9% convertible bonds payable 5,050,000    10% bonds payable 5,920,000      Total long-term debt $11,970,000 Shareholders’ equity    Preferred stock, 5% cumulative, $50 par...
Amy Dyken, controller at Sweet Pharmaceutical Industries, a public company, is currently preparing the calculation for...
Amy Dyken, controller at Sweet Pharmaceutical Industries, a public company, is currently preparing the calculation for basic and diluted earnings per share and the related disclosure for Sweet’s financial statements. Below is selected financial information for the fiscal year ended June 30, 2020. Sweet Pharmaceutical Industries Selected Balance Sheet Information June 30, 2020 Long-term debt    Notes payable, 11% $1,010,000    8% convertible bonds payable 5,050,000    11% bonds payable 5,950,000      Total long-term debt $12,010,000 Shareholders’ equity    Preferred stock, 6% cumulative, $50 par...
ART A (20 marks) Beta Drug and Chemical Ltd is undertaking a number of research and...
ART A Beta Drug and Chemical Ltd is undertaking a number of research and development projects, including the following project. Beta has been in the industry for a long time and has a network of suppliers / retailers it can rely on for any new product introduced. Project Interion: 2018: A new organic compound, DTT-phenol, has been discovered and there is a lot of interest in what this new compound can do. Beta spends $200,000 on various costs to synthesise...
Amy Dyken, controller at Crane Pharmaceutical Industries, a public company, is currently preparing the calculation for...
Amy Dyken, controller at Crane Pharmaceutical Industries, a public company, is currently preparing the calculation for basic and diluted earnings per share and the related disclosure for Crane’s financial statements. Below is selected financial information for the fiscal year ended June 30, 2020. Long-term debt    Notes payable, 10% $1,020,000    9% convertible bonds payable 4,970,000    10% bonds payable 5,980,000      Total long-term debt $11,970,000 Shareholders’ equity    Preferred stock, 5% cumulative, $50 par value, 95,000 shares authorized, 23,750 shares issued and outstanding $1,187,500...
Highnix Electronics Sdn Bhd develops and manufactures computer components and its year end was 31 December...
Highnix Electronics Sdn Bhd develops and manufactures computer components and its year end was 31 December 2018 . The company has a large factory, and two warehouses, one of which is off-site. You are an audit supervisor of Tipah & Co and the final audit is due to commence shortly. Draft financial statements show total assets of RM23.2m and profit before tax of RM6.4m. The following three matters have been brought to your attention: Inventory valuation Your firm attended the...
Using the model proposed by Lafley and Charan, analyze how Apigee was able to drive innovation....
Using the model proposed by Lafley and Charan, analyze how Apigee was able to drive innovation. case:    W17400 APIGEE: PEOPLE MANAGEMENT PRACTICES AND THE CHALLENGE OF GROWTH Ranjeet Nambudiri, S. Ramnarayan, and Catherine Xavier wrote this case solely to provide material for class discussion. The authors do not intend to illustrate either effective or ineffective handling of a managerial situation. The authors may have disguised certain names and other identifying information to protect confidentiality. This publication may not be...
ADVERTISEMENT
Need Online Homework Help?

Get Answers For Free
Most questions answered within 1 hours.

Ask a Question
ADVERTISEMENT